Microscopic imaging at the nanometer level has been automated resulting in Gigabyte images, similar to Google earth. However, the absence of a ground-truth database in electron microscopy (EM) poses a ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), currently valued at $5.59 billion with an impressive 89.62% gross profit margin, announced Wednesday its proposed public offering of $150 million ...

Rhythm plans to consult with the FDA and European regulators regarding a Phase 3 trial design. Leerink Partners has initiated coverage on Rhythm Pharmaceuticals with an Outperform rating, citing the ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), currently valued at $5.59 billion with an impressive 89.62% gross profit margin, announced Wednesday its proposed public offering of $150 ...

Investing.com - Stifel maintained its Buy rating and $94.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM), which currently trades at $82.20 and sports a $5.19 billion market cap, following ...